When was Sarepta founded?

Sarepta was founded in 1980 and raised its 1st funding round 26 years after it was founded.

Where is Sarepta located?

Sarepta is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Sarepta have?

As of May 31, 2026, the latest employee count at Sarepta is 1159.

Is Sarepta a funded company?

Sarepta is a funded company, having raised an undisclosed amount across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Dec 01, 2006.

When was the latest funding round of Sarepta?

Sarepta's latest funding was a $***** Post IPO round on Feb 28, 2020, with participation from 0 investor.

What is the annual revenue of Sarepta?

Annual revenue of Sarepta is more than $1B as on Dec 31, 2025

Where does Sarepta rank among its competitors?

Sarepta ranks 48th amongst 821 active competitors, of which 284 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Sarepta?

Sarepta's top competitors include BridgeBio, Alnylam and Alexion. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Sarepta - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of RNA-targeted therapeutics for the treatment of rare and infectious diseases. The company engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. It has a proprietary antisense Phosphorodiamidate Morpholino Oligomers platform to design targeted therapies. The company develops pipeline of products for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and more.

Website: www.sarepta.com/
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

1980

Location

Cambridge, United States

Stage

Public

Latest Funding Round

Post IPO, Feb 28, 2020, $*****

Investors

Avoro Capital & 13 more

Ranked

48^th among 821 active competitors

Annual Revenue

$1B+ as on Dec 31, 2025

Employee Count

1,159 as on May 31, 2026

Investment & Acquisitions

LEXEO Therapeutics & 5 more

Similar Companies

BridgeBio & 999 more

Exit Details

Public

View Sarepta's full profile

Sarepta is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Sarepta Therapeutics, Inc. CIN: 930797222 , United States, Active	Dec 26, 999	$1B+ (As on Dec 31, 2025)	1354 (As on Dec 31, 2024)	-

Sarepta got listed on Jun 03, 1997.

Click here to take a look at Sarepta's IPO in detail

Sarepta has raised funding over 8 rounds. Its first funding round was on Dec 01, 2006. Sarepta has 14 institutional investors.

Here is the list of recent funding rounds of Sarepta:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 28, 2020	5435442	Post IPO	5514006	4633334	4372092	4890362
Nov 25, 2019	9687419	Post IPO	1959743	1849564	1897208	4891540
Oct 06, 2015	7472414	Post IPO	8458142	4159934	4256879	Morgan Stanley & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Sarepta's funding rounds and investors

Sarepta's employee count trend

Sarepta has 1,159 employees as of May 26. Here is Sarepta's employee count trend over the years:

Uncover Sarepta's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sarepta include BridgeBio, Alnylam and Alexion. Here is the list of Top 10 competitors of Sarepta, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 27 others	77/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
7th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	71/100
8th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
9th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
10th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Flagship Pioneering, Arch Venture Partners ... & 6 others	70/100
48th	Sarepta 1980, Cambridge (United States), Public	Developer of RNA-targeted therapeutics for the treatment of rare and infectious diseases	-	Avoro Capital, Roth Capital Partners & 12 others	63/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Sarepta's competitors? Click here to see the top ones

Sarepta has made 5 investments in companies including LEXEO Therapeutics and StrideBio. Sarepta has also acquired 1 companies including Myonexus Therapeutics.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Aug 28, 2023	Investments	LEXEO Therapeutics	2018	New York City (United States)
Mar 16, 2021	Investments	StrideBio	2015	Durham (United States)
Oct 22, 2020	Investments	AAVANTIBio	2017	Gainesville (United States)